Owl Creek Asset Management’s Apexigen, Inc. Common Stock APGN Stock Holding History

Owl Creek Asset Management’s Portfolio APGN Stock Details APGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-15,000	Closed	-$151K	–	427
2022 Q1	$151K	Buy	+15,000	New	+$150K	0.01%	228

Other funds holding APGN

Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return

Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return

Owl Creek Asset Management's APGN Position: Q2 2022 in Review

Owl Creek Asset Management sold out of Apexigen, Inc. Common Stock (APGN) in Q2 2022, closing a stake of 15,000 shares — an estimated $151K sold.

Owl Creek Asset Management first reported a position in APGN in Q1 2022 and held it in 1 quarter. The position peaked at $151K in Q1 2022. 27 funds tracked by Wall St. Rank hold APGN as of Q2 2022.

Owl Creek Asset Management reported no remaining Apexigen, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Owl Creek Asset Management sold 15,000 Apexigen, Inc. Common Stock shares in Q2 2022, an estimated $151K.
Owl Creek Asset Management first reported a position in Apexigen, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
Owl Creek Asset Management's Apexigen, Inc. Common Stock position peaked at $151K in Q1 2022.
27 funds tracked by Wall St. Rank held Apexigen, Inc. Common Stock as of Q2 2022.

Based on Owl Creek Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.